{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:31:41Z","timestamp":1788615101245,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Food allergies affect up to 8% of children and are a major cause of anaphylaxis, reduced quality of life, and healthcare use. Oral immunotherapy (OIT) can induce desensitization but is limited by adverse reactions, tolerability challenges, and variable long-term outcomes. Emerging biologic therapies- particularly omalizumab and dupilumab- may improve the safety and efficiency of desensitization when used alone or with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review evidence on biologic-assisted immunotherapy and alternative desensitization approaches in pediatric food allergy, focusing on efficacy, sustained unresponsiveness, safety, treatment efficiency, and clinical applicability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review following PRISMA 2020 guidelines was conducted using PubMed, with supplementary searches of Google Scholar and SciSpace (2015\u20132025), to identify interventional studies of biologic therapies, OIT, sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT), and combination approaches in children &amp;lt;\u200918 years with IgE-mediated food allergy. Studies were synthesized using a narrative qualitative approach. Desensitization was defined as increased tolerated dose during active therapy; reaction threshold as the dose provoking symptoms; sustained unresponsiveness (SU) as absence of symptoms after treatment cessation; and tolerance as durable long-term nonreactivity independent of therapy. Risk of bias for randomized trials was assessed using the Cochrane Risk of Bias 2 (RoB2) tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 505 records, 17 studies met inclusion criteria. Omalizumab-assisted OIT demonstrated higher desensitization rates (approximately 67%\u201385%) and fewer adverse events compared with OIT alone (approximately 30%\u201340%), though effect sizes varied. Dupilumab showed modest improvements in tolerability with smaller effects on desensitization. Omalizumab monotherapy increased reaction thresholds across multiple allergens. SLIT and EPIT demonstrated favorable safety with moderate efficacy, particularly in younger children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence suggests biologic-assisted immunotherapy- particularly omalizumab with OIT- may improve desensitization and safety in pediatric food allergy, though findings are limited by heterogeneity, sample size, and risk of bias. Larger trials are needed to confirm long-term durability, optimize protocols, and assess cost-effectiveness. SLIT and EPIT may offer safer alternatives for selected high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1781735","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:40:02Z","timestamp":1782106802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Biologic-assisted immunotherapy for pediatric food allergy: a systematic review"],"prefix":"10.3389","volume":"7","author":[{"given":"Anthony","family":"Mayer","sequence":"first","affiliation":[{"name":"Idaho College of Osteopathic Medicine","place":["Idaho, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/ph18030437","article-title":"Omalizumab and oral immunotherapy in IgE-mediated food allergy in children: a systematic review and a meta-analysis","volume":"18","author":"Buono","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy","volume":"80","author":"Chinthrajah","year":"2024","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaci.2017.03.028","article-title":"Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy","volume":"140","author":"Frischmeyer-Guerrerio","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e14273","DOI":"10.1111\/pai.14273","article-title":"Early age peanut oral immunotherapy is safe and effective at achieving desensitization in 27 pediatric patients with peanut allergy","volume":"35","author":"Hemler","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/Life15050681","article-title":"Omalizumab in food allergy in children: current evidence and future perspectives","volume":"15","author":"Indolfi","year":"2025","journal-title":"Life"},{"key":"B7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1617153","DOI":"10.3389\/fimmu.2025.1617153","article-title":"Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons","volume":"16","author":"Kulis","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00005-016-0420-z","article-title":"The use of omalizumab in food oral immunotherapy","volume":"65","author":"Labrosse","year":"2017","journal-title":"Arch Immunol Ther Exp"},{"key":"B10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e85550","DOI":"10.7759\/cureus.85550","article-title":"The role of omalizumab as an adjunct to oral immunotherapy in pediatric food allergy: a systematic review","volume":"17","author":"Mustafa","year":"2025","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101069","DOI":"10.1016\/j.waojou.2025.101069","article-title":"Biologics in IgE-mediated food allergy: a systematic review and meta-analysis of interventional studies","volume":"18","author":"Nurmatov","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/all.16129","article-title":"Immunotherapy and biologics in the management of IgE-mediated food allergy: systematic review and meta-analyses of efficacy and safety","volume":"79","author":"Riggioni","year":"2024","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1111\/all.15217","article-title":"Phase 2, randomized multi oral immunotherapy with omalizumab \u201creal life\u201d study","volume":"77","author":"Sindher","year":"2022","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1016\/j.jaip.2024.08.056","article-title":"Omalizumab implementation in practice: lessons learned from the OUtMATCH study","volume":"12","author":"Vickery","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMOA1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1781735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:40:03Z","timestamp":1782106803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1781735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":19,"alternative-id":["10.3389\/falgy.2026.1781735"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1781735","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1781735"}}